Hikma Pharmaceuticals Plc (LON:HIK) had its price target dropped by equities researchers at HSBC from GBX 1,985 ($24.80) to GBX 1,800 ($22.49) in a report issued on Friday. The brokerage presently has a “hold” rating on the stock. HSBC’s price objective points to a potential upside of 10.84% from the company’s current price.

A number of other research analysts also recently commented on the company. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a report on Friday. Jefferies Group reduced their target price on Hikma Pharmaceuticals Plc from GBX 2,500 ($31.23) to GBX 2,000 ($24.99) and set a “buy” rating on the stock in a report on Friday. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 2,350 ($29.36) target price on shares of Hikma Pharmaceuticals Plc in a report on Thursday, November 10th. Barclays PLC reaffirmed an “overweight” rating and set a GBX 2,900 ($36.23) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 9th. Finally, Morgan Stanley reduced their target price on Hikma Pharmaceuticals Plc from GBX 2,700 ($33.73) to GBX 2,500 ($31.23) and set an “equal weight” rating on the stock in a report on Friday, August 12th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of GBX 2,337.40 ($29.20).

Analyst Recommendations for Hikma Pharmaceuticals Plc (LON:HIK)

Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1750.00 on Friday. The stock’s market capitalization is GBX 3.96 billion. The company has a 50 day moving average price of GBX 1,893.92 and a 200-day moving average price of GBX 2,205.15. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,575.00 and a 1-year high of GBX 2,703.00.

In other Hikma Pharmaceuticals Plc news, insider Darwazah,Said bought 200,000 shares of the stock in a transaction that occurred on Friday, August 26th. The shares were purchased at an average cost of GBX 2,160 ($26.99) per share, for a total transaction of £4,320,000 ($5,397,301.35). Also, insider Al-Husry,Ali bought 140,000 shares of the stock in a transaction that occurred on Wednesday, August 31st. The stock was acquired at an average price of GBX 2,150 ($26.86) per share, for a total transaction of £3,010,000 ($3,760,619.69).

Hikma Pharmaceuticals Plc Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.